SCLP Share Price Performance
UK£0.11
0.03 (42.41%)
63.7% undervalued intrinsic discount
UK£0.31
Fair Value
Price UK£0.11
AnalystConsensusTarget UK£0.31
Fair ValueUK£0.31
Share Pricen/a
Scancell Holdings plc Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
SCLP Community Narratives
AN
Fair Value UK£0.31 63.7% undervalued intrinsic discount
Cancer Immunotherapies Will Benefit From Growing Checkpoint Inhibitor Adoption
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Cancer Immunotherapies Will Benefit From Growing Checkpoint Inhibitor Adoption
Catalysts About Scancell Holdings Scancell Holdings develops novel cancer immunotherapies and oncology antibodies designed to improve survival outcomes in patients with solid tumors. What are the underlying business or industry changes driving this perspective?Read more
21
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
UK£0.31
63.7% undervalued intrinsic discount
Fair Value
Profit Margin
31.68%
Future PE
4.87kx
Price in 2028
UK£0.38
Trending Discussion
Recently Updated Narratives
AN
Cancer Immunotherapies Will Benefit From Growing Checkpoint Inhibitor Adoption
Fair Value: UK£0.31 63.7% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Scancell Holdings plc Key Details
Last Reported Earnings
Oct 31, 2025
Next Reporting Earnings
n/a
- -0.0053
- 94.95%
- -116.98%
- -189.5%
About SCLP
- Founded
- 1996
- Employees
- 60
- CEO
- WebsiteView website
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company provides GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which romotes receptor clustering thereby improving immune signalling. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.
